Abstract
Anticoagulant fucoidan fractions of different molecular weight and sulfate content
were prepared and investigated for their effects on platelet function in vitro. The
fucoidan fractions were incubated with human platelet rich plasma (PRP) at concentrations
of 5, 10 and 50 μg/ml. Platelet activation was subsequently studied by a standard
aggregation assay and flow cytometric determination of the activation dependent platelet-surface
markers CD62p (P-selectin, GMP-140) and CD63 (GP53). All fucoidan fractions induced
irreversible platelet aggregation in a dose-dependent manner. Comparing fractions
of identical molecular weight (100 kDa) the low sulfate content fucoidan FF5 (S=7,6%)
exerted a significantly greater effect than the highly sulfated fucoidan FF7 (S= 10,2%)
over the whole concentration range (n=5, P<0,05). Among fractions of identical sulfate
content fucoidan-induced platelet aggregation was also found to depend on the molecular
weight of the fucoidan. At concentrations of 10 and 50 μg/ml the high molecular weight
fraction FF7/1 (150 kDa) showed a significantly greater effect than the 50 kDa fraction
FF7/3 (24,8 ± 6,7 vs. 7,0 ± 3,5 and 54,6 ± 13,5 vs. 15,0 ± 9,0%, respectively; mean
± SD, n=5, P<0,05). The molecular weight dependence of the fucoidan effect was also
reflected by the flow cytometric data. Coincubation of FF7/1 and FF7/3 (10μg/ml) with
PRP increased the number of CD62p and CD63 positive platelets by 9,0 ± 3,3 vs. 2 ±
1,9 and 7,1 ± 2,4 vs. 3,2 ± 2,6% over control values, respectively (n=5, P< 0,05).
In conclusion, our results show that the low molecular weight fucoidan FF7/3 combines
potent anticoagulant and fibrinolytic properties with only minor platelet activating
effects and is therefore a suitable substance for further pharmacological studies.
© 1997 Elsevier Science Ltd
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Thrombosis ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Isolation of anticoagulant fractions from crude fucoidan.Proc. Soc. Exp. Biol. Med. 1957; 94: 404-409
- New natural polysaccharides with potent antithrombic activity: fucans from brown algae.Biomaterials. 1989; 10: 363-368
- Antithrombin activity of fucoidan.J. Biol. Chem. 1989; 264: 3618-3623
- Fibrinolytic and anticoagulant activities of highly sulfated fucoidan.Biochem. Pharmacol. 1992; 43: 1853-1858
- Preparation of oversulfated fucoidan fragments and evaluation of their antithrombotic activities.Thromb. Res. 1993; 72: 247-256
- Fucoidan is a novel non-anticoagulant inhibitor of intimal hyperplasia.Biochem. Biophys. Res. Commun. 1992; 184: 773-781
- The three processes leading to post PTCA restenosis: dependence on the lesion substrate.Thromb. Haemostasis. 1995; 74: 552-559
- A study on the anticoagulant and fibrinolytic activities of a crude fucoidan from the edible brown seaweed Laminaria religiosa, with special reference to its inhibitory effect on the growth of sarcoma-180 ascites cells subcutaneously implanted into mice.Kitasato Arch. of Exp. Med. 1987; 60: 105-121
BRUHN, T., DÜRIG, J., KRAISELBURD, E.N., DE CLERCQ, BRUHN, H.D., AND BÉRESS, L. Antiviral and anticoagulant activity of polysaccharides from marine brown algae. In: Biochemical Aspects of Marine Pharmacology. Eds.: Lazarovici, P., Spira, M.E., Zlotkin, E., Alaken Inc., Fort Collins, Colorado, 187–208, 1996.
- Anticoagulant activity of dextran derivatives..Biomaterials. 1985; 6: 198-202
- Assay of antiplasmin α 2-activity by means of a plasmin specific peptide substrate.Thromb. Res. 1978; 12: 1147-1156
- Quantitative investigations into the aggregation of blood platelets.J. Physiol. 1962; 162: 927-929
- A revised structure for fucoidan may explain some of its biological activities.J. Biol. Chem. 1993; 268: 21770-21776
- Effect of heparin and heparin fractions on platelet aggregation.J. Clin. Invest. 1980; 65: 64-73
- Detection of platelet activation using specific monoclonal antibodies.Blood Cells. 1990; 16: 85-96
- Desmopressin stimulates expression of P-selectin on human platelets in vitro.J. Lab. Clin. Med. 1995; 126: 401-409
- Morphologic and ultrastructural evidence of interleukin-6 induced platelet activation.Am. J. Hematol. 1995; 48: 92-99
- Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63 as markers of in vivo platelet activation in malignancy.Eur. J. Haematol. 1995; 55: 145-151
- Platelet membrane activation markers are predictive for increased risk of ischemic events after PTCA.Circulation. 1993; 88: 37-42
- Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry.Blood. 1988; 70: 307-315
- Thrombin binding to platelets and their activation in plasma.Br. J. Haematol. 1994; 88: 592-600
- Heparin-induced thrombocytopenia.Blood Rev. 1988; 2: 108-114
- Heparin binding to resting and activated platelets.Blood. 1989; 74: 238-243
- Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.J. Cell. Biol. 1990; 111: 765-772
- Selectin GMP-140 (CD62; PADGEM) binds to sialosyl-Lea and sialosyl-Lex, and sulfated glycans modulate this binding.Biochem. Biophys. Res. Commun. 1991; 181: 1223-1230
GUTENSOHN, K., BRUHN, T., KÖSTER, R., DÜRIG, J., KAEHLER, J., ABU, J., AND KUEHNL, P. Effects of fucoidan fractions on platelet antigens and proliferation of smooth muscle cells. Abstract, 27. Hämophilie-Symposium, Hamburg, 1996.
Article info
Publication history
Accepted:
January 31,
1997
Received in revised form:
January 31,
1997
Received:
August 19,
1996
Identification
Copyright
© 1997 Elsevier Science Ltd. Published by Elsevier Inc. All rights reserved.
